Erste Group Bank Brokers Increase Earnings Estimates for NVO

Novo Nordisk A/S (NYSE:NVO) – Stock analysts at Erste Group Bank lifted their FY2027 earnings estimates for shares of Novo Nordisk A/S in a research note issued to investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.24 per share for the year, up from their previous estimate of $3.20. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.39 per share.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%.

A number of other brokerages have also weighed in on NVO. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. BMO Capital Markets reaffirmed a “market perform” rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a report on Thursday. Finally, Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Five analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $65.81.

Novo Nordisk A/S Trading Up 0.7%

Shares of Novo Nordisk A/S stock opened at $47.59 on Monday. The firm has a market cap of $212.49 billion, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 4.31 and a beta of 0.76. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company’s 50-day simple moving average is $47.07 and its 200-day simple moving average is $44.81. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Loomis Sayles & Co. L P raised its holdings in shares of Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock worth $871,848,000 after acquiring an additional 969,916 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after acquiring an additional 717,719 shares during the last quarter. Morgan Stanley increased its position in Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after purchasing an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Novo Nordisk A/S in the 1st quarter valued at about $287,660,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be given a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a dividend yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 42.79%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.